Research programme: exosome-based therapeutics - Codiak BioSciences

Drug Profile

Research programme: exosome-based therapeutics - Codiak BioSciences

Latest Information Update: 18 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Codiak BioSciences
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Nov 2016 Codiak plans a phase I trial for Pancreatic cancer in USA (Codiac BioSciences website, November 2016)
  • 17 Nov 2015 Early research in Cancer in USA (unspecified route)
  • 17 Nov 2015 CodiaK Biosciences enters into a licensing and sponsored research agreement with University of Texas M. D. Anderson Cancer Center for exosome-based therapeutics and diagnostics (9207235; 9207236) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top